Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 8/20 | 0.43 |
| ▸ | RAB9A | P51151 | 8/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25698386 | 0.83 | CNR1 (0.47) | CNR1NPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL29215323 | 0.81 | HPGD (0.58) | NPC1RAB9AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30898843 | 0.81 | HPGD (0.58) | NPC1RAB9AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL22912737 | 0.81 | RAB9A (0.46) | CNR1NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL25690420 | 0.80 | CNR1 (0.44) | CNR1NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL31033036 | 0.77 | RAB9A (0.39) | NPC1RAB9AKMT2AALDH1A1MAPK1 | |
| SCHEMBL25235168 | 0.77 | NPC1 (0.43) | NPC1RAB9AKMT2AALDH1A1MAPK1 | |
| SCHEMBL16599633 | 0.77 | NPC1 (0.44) | CNR1NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL12163955 | 0.76 | P2RX7 (0.69) | CNR1NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL1179778 | 0.75 | CYP1A2 (0.61) | NPC1RAB9AKMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163022-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4452963-A1 | PARP1 INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452256-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | Astrazeneca AB (SE) | 2024-10-30 | — | — | EP | disclosed |
| CN-118696036-A | PARP1 inhibitors | 突触活化疗法股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-11795158-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2023-10-24 | — | — | US | disclosed |
| US-11795158-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2023-10-24 | — | — | US | disclosed |
| WO-2023122140-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122140-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118085-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118085-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4172152-A1 | QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS | Astrazeneca AB (SE) | 2023-05-03 | — | — | EP | disclosed |
| WO-2021260092-A1 | QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS | ASTRAZENECA AB (SE) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795158-B2 | Chemical compounds | CYP11B2, CYP11B1, CYP4B1 | CNR1 1747/4885NPC1 285/4885RAB9A 2045/4885 |
| US-20250163022-A1 | PARP1 INHIBITORS | PARP1, PARP11, PARP12 | CNR1 3116/4885NPC1 1914/4885RAB9A 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.